Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,468 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Testing Clear all
Enrolling by invitation Phase 3 Interventional

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05076617
View directory record Official record
Conditions
Stereotypical Prolonged Seizures
Interventions
Staccato alprazolam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
48
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA

NCT02865434
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Tc99m-tilmanocept, SPECT Imaging (60 Minutes post-injection), SPECT Imaging (180 Minutes post-injection), Whole body planar SPECT imaging (15 Minutes post-injection), Whole body planar SPECT imaging (60 Minutes post-injection), Whole body planar SPECT imaging (180 Minutes post-injection), Whole body planar SPECT imaging (18-20 Hours post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after injection), Blood Collection for PK Testing (15 minutes post injection), Blood Collection for PK Testing (60 minutes post injection), Blood Collection for PK Testing (180 minutes post injection), Blood Collection for PK Testing (18-20 hours post injection), Planar Image with both Hands in Field of View
Drug · Procedure
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 28, 2026, 1:23 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A CHW Intervention to Identify and Decrease Barriers to COVID 19 Testing & Vaccination

NCT05473936
View directory record Official record
Conditions
Vaccine Hesitancy, COVID-19 Testing, Community Health Workers
Interventions
Community Health Worker led curriculum
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
16 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 28, 2026, 1:23 AM EDT
Terminated Phase 2 Interventional Results available

Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)

NCT00668785
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Macular Edema
Interventions
ranibizumab
Drug
Lead sponsor
Jumper, J. Michael, M.D.
Individual
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Goat or Cow Milk Based Infant Formula GMS

NCT06312059
View directory record Official record
Conditions
Growth
Interventions
Advance Infant Formula Powder, "Kendamil Cow milk test product, "Kendamil goat milk test product
Other
Lead sponsor
Kendal Nutricare Ltd
Industry
Eligibility
Up to 14 Days
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Phase 2Phase 3 Interventional Results available

IVPCA in the Management of Pain Following Major Intracranial Surgery

NCT00286221
View directory record Official record
Conditions
Intracranial Surgery
Interventions
PCA fentanyl, PRN fentanyl
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 28, 2026, 1:23 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Proactive Reduction of Outpatient Malpractice: Increasing Safety, Efficiency, and Satisfaction

NCT01758315
View directory record Official record
Conditions
Medical Malpractice, Patient Safety
Interventions
Training and in-office coaching
Other
Lead sponsor
Massachusetts Department of Health
Government
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 1, 2013 · Synced Oct 28, 2026, 1:23 AM EDT
Active, not recruiting Not applicable Interventional

Memory Retrieval and Encoding Investigated by Neural Stimulation

NCT04286776
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Direct electrical stimulation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
11
States / cities
Aurora, Colorado • Atlanta, Georgia • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 28, 2026, 1:23 AM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS)

NCT03697993
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Fosfomycin tromethamine, Levofloxacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Sylmar, California • Torrance, California • Decatur, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 28, 2026, 1:23 AM EDT
Active, not recruiting Phase 2 Interventional

Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.

NCT05690204
View directory record Official record
Conditions
Gout
Interventions
SAP-001
Drug
Lead sponsor
Shanton Pharma Pte. Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
Sacramento, California • San Diego, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pilot Study of GLY-LOW Supplementation in Postmenopausal Women With Obesity

NCT06242535
View directory record Official record
Conditions
Insulin Resistance, Obesity, Cardiovascular Diseases, Cognitive Impairment, Physical Disability, Depression, Inflammation, Hormone Deficiency, Physical Inactivity, Hyperlipidemias, Hypertension, Overeating
Interventions
GLY-LOW
Biological
Lead sponsor
Hoskinson Health and Wellness Clinic
Industry
Eligibility
56 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Gillette, Wyoming
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Phase 4 Interventional

Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions

NCT01283425
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
InsuPatch
Device
Lead sponsor
Insuline Medical Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Phase 1 Interventional

Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL

NCT01333046
View directory record Official record
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions
Antigen-Escalation Stage, Dose-Escalation Stage, azacytidine and multiTAA T cells Stage, Pediatric multiTAA T cells Stage
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 28, 2026, 1:23 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Sensory Training for Orientation and Balance

NCT04331561
View directory record Official record
Conditions
Motion Sickness, Vertigo, Dizziness, Fall
Interventions
sensory re-weighting
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 59 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Phase 1 Interventional

Safety and Effects on Responses to Stress and Pain of Natural Medical Marijuana Products

NCT04226690
View directory record Official record
Conditions
Pain
Interventions
Active CBD/THC Dose 1, Active CBD/THC Dose 2, matched placebo comparator
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 68 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 28, 2026, 1:23 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

NCT06317662
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Interventions
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Leucovorin, Levoleucovorin, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Prednisolone, Prednisone, Therapeutic Hydrocortisone, Thioguanine, Venetoclax, Vincristine
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 365 Days
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
116
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Enhancing Indoor, Community, and Advanced Wheelchair Skills in Spinal Cord Injury (SCI)

NCT00434018
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Wheelchair Skills Training, Basic Health Education
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 75 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
Tampa, Florida • Augusta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 28, 2026, 1:23 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise

NCT07226583
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Exercise Physiology
Interventions
Standard-of-Care Guidance (SoC), Usual Care (UC), netIOB & Exercise Toolkit (NEXT), Continuous Glucose Monitoring, Continuous Ketone Monitoring
Behavioral · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 28, 2026, 1:23 AM EDT
Active, not recruiting Not applicable Interventional

Assessment of Combined CCM and ICD Device in HFrEF

NCT05855135
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy, Non-ischemic Cardiomyopathy, Ischemic Cardiomyopathy, Sudden Cardiac Arrest, Arrhythmias, Cardiac, Ventricular Tachycardia, Ventricular Fibrillation
Interventions
OPTIMIZER® Integra CCM-D System (Treatment Arm)
Device
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
59
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 28, 2026, 1:23 AM EDT
Terminated Phase 1 Interventional Results available

Insulin Tolerance Test Study in Patients With Type 1 Diabetes

NCT04026750
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
Pitolisant
Drug
Lead sponsor
High Point Clinical Trials Center
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

NCT04996797
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tulisokibart, Companion Diagnostic (CDx) Testing, Placebo
Drug · Device · Other
Lead sponsor
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
29
States / cities
Mobile, Alabama • Phoenix, Arizona • Sun City, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 28, 2026, 1:23 AM EDT
Recruiting Not applicable Interventional

Evaluation of the Safety of Loargys Arginine Test System in Loargys-treated Patients

NCT07573059
View directory record Official record
Conditions
ARG1 Deficiency
Interventions
Loargys Arginine Test System
Device
Lead sponsor
Immedica Pharma US Inc
Industry
Eligibility
0 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Perinatal Nurse Home Visiting Enhanced With mHealth Technology

NCT01688427
View directory record Official record
Conditions
Domestic Violence, Intimate Partner Violence
Interventions
Standard IPV Assessment, Standard DOVE Intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
433 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 28, 2026, 1:23 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma

NCT00590720
View directory record Official record
Conditions
Asthma
Interventions
MEDI528 50 mg, PLACEBO
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
San Diego, California • Denver, Colorado • Waterbury, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2014 · Synced Oct 28, 2026, 1:23 AM EDT